Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Abstract: Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demo...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2019-08-01
|
| coleção: | Blood Advances |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S2473952920300318 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|